介入放射学/肿瘤免疫学新焦点 IR/IO New Focus 我们打盹......我们输了!!! ! Ipilimumab: $1 billion sales 2015; Nivolimumab: $2 billion /year What is IO Immunotherapy? IRs can potentiate local-regional systemic synergy What systemic effec...
Local treatments: Surgery, Radiotherapy Systemic treatments: Chemotherapy, Targeted therapy, Immunotherapy Passive immunotherapy - Killer T cells (NK, LAK, TIL, CTL) - Antibodies, toxin conjugates Active immunization / vaccines - Tumor ant...
1...
引自苏大二院介入治疗科文献复习 射频消融术诱导抗原呈递细胞浸润,增强肿瘤诱导免疫 评估次全射频(RF)消融对小鼠肿瘤模型中肿瘤特异性免疫应答的影响,并探讨肿瘤内树突状细胞(ITDCs)在其中的作用。 材料和方法: 动物模型工作根据批准的方案进行,并符...
射频消融术诱导抗原呈递细胞浸润,增强肿瘤诱导免疫 评估次全射频(RF)消融对小鼠肿瘤模型中肿瘤特异性免疫应答的影响,并探讨肿瘤内树突状细胞(ITDCs)在其中的作用。 材料和方法: 动物模型工作根据批准的方案进行,并符合国家癌症研究所动物护理和使用...
RFA (or TACE) + Anti-CTLA4 Checkpoint Inhibitor for HCC 12/14 HCV Reduced viral load Reduced AFP,6 week biopsy: CD8 up only if response 57% PFS @ 6 mo heavily pre-treated pts 消融和Anti-CTLA4后远处肿瘤的镜下表现 Baseline Immune infiltrate...
Curr Opin Gastroenterol 2020 Feb 25[Online ahead of print] New Systemic Agents for Hepatocellular Carcinoma: An Update 2020 Johann von Felden 1 Affiliations expand PMID: 32101985 DOI: 10.1097/MOG.0000000000000626 Abstract Purpose of review...